Catechol-O-methyltransferase decreases levodopa toxicity in vitro

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• High concentrations of levodopa (L-DOPA) exhibit in vitro toxicity, raising concerns about potential acceleration of nigrostriatal neuron degeneration in Parkinson's disease patients.
• In vivo studies suggest levodopa may not be toxic, hinting at a potential defense mechanism.
• Metabolic shunting of levodopa excess to 3-O-methyldopa by catechol-O-methyltransferase (COMT) is a proposed protective pathway.

Purpose of the Study:

• To investigate the role of 3-O-methylation by COMT in modulating levodopa's toxicity in neuronal cultures.
• To determine if inhibiting COMT affects levodopa's cytotoxicity by altering 3-O-methyldopa levels.

Main Methods:

• Neuronal cultures (mouse cerebellar granule neurons, PC12, neuroblastoma cells) were exposed to levodopa.
• Cell viability was assessed using neutral red staining with and without purified COMT or the COMT inhibitor tolcapone.
• Levodopa auto-oxidation was monitored spectrophotometrically.

Main Results:

• 3-O-methyldopa was found to be non-toxic to the examined cell types.
• Addition of purified COMT to levodopa prevented its auto-oxidation and significantly reduced its in vitro cytotoxicity.
• The presence of tolcapone reversed the protective effects of COMT, indicating the role of 3-O-methyldopa formation.

Conclusions:

• Catechol-O-methyltransferase attenuates levodopa's in vitro toxicity by metabolizing it into the non-toxic compound 3-O-methyldopa.
• This metabolic pathway represents a significant defense mechanism against levodopa-induced neurotoxicity.